Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;23(3):214-9.
doi: 10.1016/j.smim.2011.07.003. Epub 2011 Aug 17.

Immune intervention in type 1 diabetes

Aaron W Michels  1 , George S Eisenbarth
Affiliations
Review

Immune intervention in type 1 diabetes

Aaron W Michels et al. Semin Immunol. 2011 Jun.

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease that results in the specific immune destruction of insulin producing beta cells. Currently there is no cure for T1D and treatment for the disease consists of lifelong administration of insulin. Immunotherapies aimed at preventing beta cell destruction in T1D patients with residual c-peptide or in individuals developing T1D are being evaluated. Networks of researchers such as TrialNet and the Immune Tolerance Network in the U.S. and similar networks in Europe have been established to evaluate such immunotherapies. This review focuses on immune intervention for the prevention and amelioration of human T1D with a focus on potential immune suppressive, antigen specific and environmental therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hypothetical stages and loss of beta cells in an individual progressing to type 1A diabetes. Reproduced with permission from Eisenbarth, GS. From www.barbardaviscenter.org
Figure 2
Figure 2
Pancreatic section from a type 1 diabetic pancreatic organ donor showing lobular destruction of insulin producing beta cells in islets. On the left, there are islets with beta cells stained for insulin while the islets on the right lack beta cells and insulin staining. The histology section comes from the JDRF nPOD program, www.jdrfnpod.org.
Figure 3
Figure 3
Anti-CD3 monoclonal antibody treatment delays loss of C-peptide in new onset patients with type 1 diabetes. From Herold et al Diabetes 54:1763-9, 2005.
See this image and copyright information in PMC

References

    1. Eisenbarth GS. Banting Lecture 2009: An Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes. Diabetes. 2010;59(4):759–774. - PMC - PubMed
    1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293–1300. - PMC - PubMed
    1. Maahs DM, Rewers M. Editorial: Mortality and renal disease in type 1 diabetes mellitus--progress made, more to be done. J Clin Endocrinol Metab. 2006;91(10):3757–3759. - PubMed
    1. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26(3):832–836. - PubMed
    1. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet. 2008;371(9626):1777–1782. - PubMed

Publication types

MeSH terms